KRRO

Korro Bio Inc

Jan 30 • 12:11PM ET

13.53

+0.22 1.64 %

Healthcare • Biotechnology • USA • NASD

Peers: BEAM EDIT NTLA CRSP RGNX FDMT VYGR ARVN SGMO CRBU

| Held by: IWM VTI LFSC IWN VXF VTWO IWC ITOT VHT IWV

Index	RUT	P/E	-	EPS (ttm)	-9.42	Insider Own	45.35%	Shs Outstand	9.40M	Perf Week	26.08%
Market Cap	127.39M	Forward P/E	-	EPS next Y	-8.10	Insider Trans	0.00%	Shs Float	5.15M	Perf Month	71.24%
Enterprise Value	78.58M	PEG	-	EPS next Q	-2.07	Inst Own	75.94%	Short Float	21.19%	Perf Quarter	-65.12%
Income	-88.42M	P/S	17.29	EPS this Y	3.63%	Inst Trans	19.00%	Short Ratio	2.00	Perf Half Y	-9.57%
Sales	7.37M	P/B	1.28	EPS next Y	10.33%	ROA	-43.65%	Short Interest	1.09M	Perf YTD	68.89%
Book/sh	10.54	P/C	1.36	EPS next 5Y	5.84%	ROE	-63.46%	52W High	55.89 -75.80%	Perf Year	-59.12%
Cash/sh	9.93	P/FCF	-	EPS past 3/5Y	57.64% 21.83%	ROIC	-62.91%	52W Low	5.20 159.93%	Perf 3Y	-94.29%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-45.55% -39.89%	Gross Margin	33.82%	Volatility	11.27% 8.39%	Perf 5Y	-99.28%
Dividend TTM	-	EV/Sales	10.66	EPS Y/Y TTM	21.61%	Oper. Margin	-1282.04%	ATR (14)	1.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.71	Sales Y/Y TTM	-	Profit Margin	-1199.53%	RSI (14)	76.12	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.71	EPS Q/Q	14.80%	SMA20	38.57%	Beta	3.02	Target Price	22.38
Payout	-	Debt/Eq	0.45	Sales Q/Q	-	SMA50	65.33%	Rel Volume	0.58	Prev Close	13.31
Employees	104	LT Debt/Eq	0.42	Earnings	Nov 12 AMC	SMA200	-29.94%	Avg Volume	544.23K	Price	13.53
IPO	Oct 03, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	25.98% 67.56%	Trades		Volume	139,765	Change	1.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-29-26	Upgrade	Piper Sandler	Neutral → Overweight	$30
Jan-29-26	Upgrade	H.C. Wainwright	Neutral → Buy	$20
Jan-29-26	Upgrade	Chardan Capital Markets	Neutral → Buy	$15
Jan-28-26	Upgrade	Oppenheimer	Perform → Outperform	$22
Jan-28-26	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$21
Nov-13-25	Downgrade	William Blair	Outperform → Mkt Perform
Nov-13-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$8
Nov-13-25	Downgrade	Raymond James	Strong Buy → Mkt Perform
Nov-13-25	Downgrade	Piper Sandler	Overweight → Neutral	$11
Nov-13-25	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-25	Downgrade	Chardan Capital Markets	Buy → Neutral	$7
Nov-13-25	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$74
Apr-16-25	Initiated	Chardan Capital Markets	Buy	$25
Jan-10-25	Initiated	Oppenheimer	Outperform	$155
Oct-21-24	Initiated	Raymond James	Strong Buy	$153
Aug-14-24	Initiated	William Blair	Outperform	$180
Mar-28-24	Reiterated	H.C. Wainwright	Buy	$100 → $115
Feb-27-24	Initiated	BMO Capital Markets	Outperform	$120
Dec-04-23	Initiated	H.C. Wainwright	Buy	$100

Show Previous Ratings

Today 07:35AM	Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? (Zacks)
03:08AM	Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE (MarketBeat)
Jan-29-26 09:35AM	First Solar downgraded, Fortinet upgraded: Wall Street's top analyst calls (The Fly) +13.86%
Jan-20-26 08:00AM	Korro to Host Virtual Analyst Day on January 27, 2026 (GlobeNewswire)
Jan-08-26 08:00AM	Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.77%
09:37AM	Loading…
Nov-13-25 09:37AM	Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing (Investor's Business Daily) -79.31%
09:45AM	Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls (The Fly)
Nov-12-25 05:59PM	This biotech is halting its work with Novo Nordisk and laying off more people (MarketWatch)
05:40PM	Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs (GlobeNewswire)
Sep-02-25 04:30PM	Korro to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire) +17.25%
Aug-12-25 07:00AM	Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) +6.25%
Jul-21-25 08:00AM	Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110 (GlobeNewswire)
May-14-25 04:05PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.26%
May-09-25 10:31AM	Korro Bio price target lowered to $53 from $130 at H.C. Wainwright (TipRanks)
04:30PM	Loading…
May-07-25 04:30PM	Korro Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -5.85% +10.55%
Apr-01-25 07:30AM	Korro Appoints Biotech Industry Veteran, Loic Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire) -8.39%
07:30AM	Korro Appoints Biotech Industry Veteran, Lo c Vincent, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Mar-28-25 06:18PM	Korro Bio: Promising Early Stage RNA Editing Company (Seeking Alpha) -5.11%
Mar-18-25 07:00AM	Korro Reports Full Year 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-17-25 07:26AM	FDA grants orphan drug status for Korro Bio's AATD therapy (Pharmaceutical Business Review)
Mar-14-25 08:00AM	KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Feb-26-25 08:00AM	Korro to Present at the TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-13-25 08:00AM	Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update (GlobeNewswire) +8.20%
Jan-07-25 08:00AM	Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -7.23%
Dec-10-24 08:00AM	CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors (GlobeNewswire)
Nov-21-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.70%
07:30AM	Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
Nov-14-24 08:00AM	Korro to Present at the Jefferies London Healthcare Conference (GlobeNewswire) -9.65%
Nov-12-24 04:05PM	Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) -11.37% -15.55%
07:25AM	Loading…
Nov-04-24 07:25AM	Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board (GlobeNewswire)
Oct-21-24 04:15PM	Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space. (Investor's Business Daily) -5.22% -7.70%
Oct-16-24 04:20PM	Wave Life Sciences Just Edited RNA. Why Its Key Rival, Korro Bio, Skyrocketed. (Investor's Business Daily) +93.66%
Sep-30-24 08:00AM	Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society (GlobeNewswire)
Sep-16-24 08:00AM	Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates (GlobeNewswire)
Sep-10-24 08:00AM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-28-24 08:00AM	Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors (GlobeNewswire)
Aug-27-24 08:00AM	Korro to Participate in Upcoming September Investor and Scientific Conferences (GlobeNewswire)
Aug-13-24 04:01PM	Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire) +9.21%
Jul-01-24 08:00AM	Korro Joins the Russell 2000 , Russell 3000 , and Russell Microcap Indexes (GlobeNewswire)
Jun-25-24 12:53PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q4 2023 (InvestorPlace)
May-30-24 04:01PM	Korro to Participate in Upcoming June Investor and Scientific Conferences (GlobeNewswire)
May-20-24 02:30PM	Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference (GlobeNewswire)
May-14-24 10:55PM	KRRO Stock Earnings: Korro Bio Beats EPS for Q1 2024 (InvestorPlace) +5.43%
04:01PM	Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer (GlobeNewswire)
Apr-18-24 08:30AM	Korro Announces $70 Million Private Placement (GlobeNewswire)
Apr-01-24 04:01PM	Korro to Participate in Upcoming Investor Conferences (GlobeNewswire) -7.90%
Mar-26-24 04:01PM	Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress (GlobeNewswire) +18.43%
Feb-27-24 09:55AM	Wall Street Analysts Believe Korro Bio, Inc. (KRRO) Could Rally 86.94%: Here's is How to Trade (Zacks) -6.08%
08:00AM	Korro to Present at the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-09-24 09:55AM	Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect? (Zacks)
Jan-18-24 08:00AM	Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio (GlobeNewswire) -5.98%
Jan-04-24 08:00AM	Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-07-23 08:00AM	Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD) (GlobeNewswire) -14.67%
Nov-28-23 08:00AM	Korro Bio Appoints Dr. Rachel Meyers to Board of Directors (GlobeNewswire) +6.45%
Nov-03-23 03:31PM	UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire) +5.94%
12:19PM	Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million (GlobeNewswire)
Aug-10-23 04:01PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results (Business Wire)
Jul-17-23 11:59AM	Frequency (FREQ) Up 77% on Merger Deal With Korro Bio (Zacks) -12.66%
Jul-14-23 11:22AM	Why Are Frequency Therapeutics Shares Surging Today (Benzinga) +77.47%
06:30AM	Korro Bio and Frequency Therapeutics Announce Merger Agreement (Business Wire)
May-12-23 04:01PM	Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results (Business Wire) -5.17%
Mar-10-23 07:30AM	Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results (Business Wire)
Feb-27-23 07:30AM	Frequency Therapeutics to Participate at Upcoming March Investor Conferences (Business Wire) +5.40%
Feb-13-23 01:55PM	Hearing loss startup to cut more than half of staff in wake of trial failure (American City Business Journals) -80.54%
11:17AM	Frequency Therapeutics' Lead Hearing Loss Program Flunks, Shifts Focus To Multiple Sclerosis, Shares Plunge (Benzinga)
08:05AM	Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire)
Dec-19-22 07:30AM	Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program (Business Wire)
Dec-15-22 07:30AM	Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Companys Second Therapeutic Candidate for Sensorineural Hearing Loss (Business Wire)
Nov-17-22 07:30AM	Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results (Business Wire) -10.05%
Nov-08-22 04:05PM	Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results (Business Wire) -9.51%
Oct-12-22 07:30AM	Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss (Business Wire) +7.47%
Aug-30-22 07:30AM	Frequency Therapeutics to Participate in September Investor and Medical Conferences (Business Wire)
Aug-09-22 04:05PM	Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results (Business Wire) -11.11% +9.00%
Jun-24-22 09:03AM	Frequency Therapeutics (NASDAQ:FREQ) one-year losses have grown faster than shareholder returns have fallen, but the stock jumps 41% this past week (Simply Wall St.) -7.59%
May-25-22 12:00PM	Frequency Therapeutics, Inc. (FREQ) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
May-18-22 07:30AM	Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference (Business Wire) -9.02%
May-04-22 04:30PM	Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results (Business Wire)
Apr-22-22 07:30AM	Frequency Therapeutics to Participate in B. Riley Securities Neuro & Ophthalmology Investor Conference (Business Wire)
Apr-08-22 05:00PM	Frequency Exchange Corp. Virtually Closes the Market (PR Newswire) -8.82%
Mar-15-22 07:30AM	Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results (Business Wire) +15.29%
Mar-10-22 06:35PM	Poseida Therapeutics, Inc. (PSTX) Beats Q4 Earnings and Revenue Estimates (Zacks) -13.70%
Feb-28-22 07:30AM	Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences (Business Wire)
Jan-14-22 05:43AM	One Frequency Therapeutics, Inc. (NASDAQ:FREQ) insider upped their stake in the previous year (Simply Wall St.)
Jan-04-22 07:30AM	Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-28-21 02:38AM	Destra Investment Trust Buys ThredUp Inc, Etsy Inc, Riskified, Sells , , 2U Inc (GuruFocus.com) +5.28%
Dec-09-21 01:18PM	Frequency Therapeutics' Hearing Loss Candidate Shows Improved Speech Perception In Noise (Benzinga)
07:30AM	Frequency Therapeutics Shares Results from FX-322-113 Severe Sensorineural Hearing Loss Study Showing Speech Perception Improvements in Noise (Business Wire)
Nov-30-21 05:53AM	Frequency Therapeutics (NASDAQ:FREQ) investors are sitting on a loss of 81% if they invested a year ago (Simply Wall St.)
Nov-15-21 12:25PM	Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results (Business Wire)
Nov-09-21 07:30AM	Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis (Business Wire)
Nov-08-21 03:00PM	Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-27-21 07:30AM	Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program (Business Wire)
Oct-21-21 07:30AM	Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint (Business Wire)
Oct-01-21 08:23AM	Do Insiders Own Lots Of Shares In Frequency Therapeutics, Inc. (NASDAQ:FREQ)? (Simply Wall St.)
Sep-22-21 11:18AM	Frequency Therapeutics' New Data Of Hearing Loss Candidate Fails To Impress Investors (Benzinga)
07:30AM	Frequency Therapeutics Announces New FX-322 Results Showing That Additional Study Participants Gain Hearing Improvements at Later Time Points (Business Wire)
Sep-08-21 07:30AM	Frequency Therapeutics to Present at Upcoming Investor Conferences (Business Wire)
Aug-30-21 05:10PM	Lifshitz Law Firm, P.C. Announces Investigations of AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Frequency Therapeutics, Inc. (NasdaqGS: FREQ), RLX Technology Inc. (NYSE: RLX), and Washington Prime Group, Inc. (NYSE: WPG) (ACCESSWIRE)

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

KRRO

Korro Bio Inc

Upgrade your FINVIZ experience